Context: In the Unified Patent Court (UPC), plaintiffs must give security if they are in a financially weak condition or if enforcement in the jurisdiction in which they are based might be impossible or unduly burdensome. The standard types of collateral are a deposit or a bond issued by an EU-based bank. Last year, the UPC’s Court of Appeal (CoA) rejected both a U.S. bank guarantee and a UK insurance policy, but with respect to the letter the decision was purely procedural: it was presented out of time (September 17, 2024 ip fray article).
What’s new: In his capacity as judge-rapporteur on two Syntorr v. Arthrex cases, Judge Tobias Pichlmaier of the Munich Local Division (LD) has ordered the provision of collateral to the tune of €2 million per case (€4 million in total), and has categorically rejected an insurance policy, even if issued by an EU-based insurer, as collateral, thereby treating the security options laid out in Rule 158 of the Rules of Procedure (RoP) as exhaustive (1, 2).
Direct impact: This is an interesting decision, but it could be reviewed by the panel and appealed from there. The plaintiff was apparently prepared for this outcome, as €2 million per case was the upper end of the range of a security amount is considered justified. It successfully opposed the defendants’ (three Arthrex entities) request for €3 million, but the statutory cap (which applies to all cases with a value exceeding €50 million) applied. Where Judge Pichlmaier agreed with the plaintiffs was that they should have six weeks to provide collateral, which is a generous time frame but apparently was deemed reasonable in light of the amount.
Wider ramifications: This may be a record for a security amount to be ordered by the UPC in connection with a single dispute. If the plaintiff appeals the rejection of an insurancy policy issued by an EU-based insurer, the question of whether the options offered by Rule 158 RoP ar strictly and literally exhaustive.
Both parties make medical devices. The UPC is not the only venue in which they are litigating. For example, there is a UK dispute over suture patents.
Counsel
Counsel for Syntorr: McDermott Will & Schulte’s Prof. Henrik Holzapfel.
Counsel for Arthrex: Noerr’s Dr. Ralph Nack.
